Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556202 · ClinicalTrials.gov registry record · Phase 3
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,936
- Enrollment target
NCT03556202 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,936 participants.
The verdict
NCT03556202, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,936 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
Interventions
- DRUG Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,936 participants |
| Start Date | 2018-09-03 |
| Est. Completion | 2022-02-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03556202
The ClinicalTrials.gov registry entry for NCT03556202 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,936 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mirikizumab is the first listed.
NCT03556202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03556202 about?
NCT03556202 is a clinical study titled "A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)". The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT03556202?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,936 participants. The study started on 2018-09-03. Estimated completion is 2022-02-07.
What interventions are being tested in trial NCT03556202?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT03556202?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.